Abstract
Melanocortin-1 receptor (MC1R) and very late antigen-4 (VLA-4, integrin α4β1) are two attractive molecular targets for developing peptide radiopharmaceuticals for melanoma imaging and therapy. MC1R- and VLA-4-targeting peptides and peptide-conjugated Cornell prime dots (C' dots) can serve as delivery vehicles to target both diagnostic and therapeutic radionuclides to melanoma cells for imaging and therapy. This review highlights the advances of MC1R- and VLA-4-targeted radiolabeled peptides and peptide-conjugated C' dots for melanoma imaging and therapy. The promising preclinical and clinical results of these new peptide radiopharmaceuticals present an optimistic outlook for clinical translation into receptor-targeting melanoma imaging and radionuclide therapy in the future.
- Molecular Imaging
- Oncology: Melanoma
- Radionuclide Therapy
- Cornell prime dots
- Melanocortin-1 receptor
- melanoma imaging and therapy
- peptide radiopharmaceuticals
- very late antigen-4
- Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
SNMMI members
Login to the site using your SNMMI member credentials
Individuals
Login as an individual user